tbuckley/cabot-search huggingface dataset:
Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia
Authors: Kensuke Kojima, Steven M. Kornblau, Vivian Ruvolo, Seshagiri Duvvuri, Richard E Davis, Min Zhang, Zhiqiang Wang, Kevin R. Coombes, Nianxiang Zhang, Yi Hua Qiu, Jared K. Burks, Peter P. Ruvolo, Sharon Shacham, Michael Kauffman, Michael Andreeff
Journal: Blood (2012)
Mother's milk.
Journal: Environmental Health Perspectives (1995)

ForumHemp can be combined with other materials to add strength.Roger Rowell, a researcher at the U.S. Forest Products Laboratory in Madison, Wisconsin, said hemp can be added to plastic products, such as fan blades, to help stiffen them.Hemp fibers are also used in clothing.The idea of using hemp is being taken seriously at governmental levels as well.Erwin Scholts, in charge of developing and diversifying agriculture at the Wisconsin Agriculture Department, called a conference last spring to explore the commercial possibilities of hemp.And the governor of Kentucky
ALCOHOL AS AN AID TO THE NATURAL PROTECTIVE AGENCIES AGAINST INFECTIONS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rochalimaea Infections
Authors: Roy T. Steigbigel
Journal: Annals of Internal Medicine (1993)

Letters15 September 1993Rochalimaea InfectionsRoy T. Steigbigel, MD and David C. Tompkins, MDRoy T. Steigbigel, MDSearch for more papers by this author and David C. Tompkins, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-6-199309150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that the papers we cited in our editorial [1] reported the isolation of Rochalimaea species from apparently immunocompetent patients who had fever and bacteremia but not the cutaneous lesions described as bacillary angiomatosis. Drs. Tappero and Koehler and their coworkers have made the important observation that these vascular lesions can also occur in immunocompetent patients [2]. Future study is needed to describe more fully the spectrum of diseases caused by these organisms and the reasons for the varying manifestations in different persons.References1. Tompkins DC, Steigbigel RT. Rochalimaea's role in cat scratch disease and bacillary angiomatosis. Ann Intern Med. 1993; 118:388-90. Google Scholar2. Tappero JW, Koehler JE, Berger TG, Cockerell CJ, Lee T-H, Busch MP, et al. Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med. 1993; 118:363-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 September 1993Volume 119, Issue 6Page: 535-536KeywordsAngiomatosisBacteremiaBartonellaFeversForecastingLesions ePublished: 15 August 2000 Issue Published: 15 September 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A NEW "MEDICAL JOURNAL."
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic and Stress-Induced Loss of NG2 Glia Triggers Emergence of Depressive-like Behaviors through Reduced Secretion of FGF2
Authors: Fikri Birey, Michelle Kloc, Manideep Chavali, Israa Hussein, Michael Wilson, Daniel J. Christoffel, Tony Chen, Michael A. Frohman, John K. Robinson, Scott J. Russo, Arianna Maffei, Adan Aguirre
Journal: Neuron (2019)
Effects of Bacterial Endotoxin on Metabolism: Role of Tryptophan Pyrrolase in Response of Mice to Endotoxin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The University Group Diabetes Program. A further statistical analysis of the mortality findings
Authors: J. Cornfield
Journal: JAMA (1971)

The basic conclusion of the University Group Diabetes Program on tolbutamide is: "the findings of this study indicate that the combination of diet and tolbutamide therapy is no more effective than diet alone in prolonging life. Moreover, the findings suggest that tolbutamide and diet may be less effective than diet alone or than diet and insulin at least in so far as cardiovascular mortality is concerned."<sup>1</sup>With no evidence of efficacy and a definite possibility of toxicity the investigators concluded that the safety of the patients still receiving tolbutamide therapy required its discontinuance and that the factual basis for this decision needed to be communicated to the biomedical scientific community. This prudent decision and moderately worded conclusion has been received by some critics with a hostility which has no discernible scientific basis. The following analysis is largely confined to Dr. Schor's analysis (see page 1671). In general, independent repetition
Carcinogen Adducts As an Indicator for the Public Health Risks of Consuming Carcinogen-Exposed Fish and Shellfish
Authors: Bruce P. Dunn
Journal: Environmental Health Perspectives (1991)

A lage variety ofenvironmental carinogens are metabolicaly activated to electrophilic metabolites that can bind to nucleic acidsand protin, formingcovantadducts.The frmationofDNAcardnogenadductsis ughttobeanecery step in the action of most carciogens.Recendy, a variety of new fluorescence, immunochemical, and radioactive- procedures hebeen dopethatalw thesensitie ofDNA-carcinogenadductsn m exposed to en nmental carcinogens.In some cases, similar procedures have been developed for protein-carcinogen adducts.In anorganim with actrve nmtaboc systems for a given carcinogen, adducts are generally much longer lived than the carcinogens that formed them.Thus, the detection ofDNA-or protdn-carcinogen adductsin aquatic foodstuffs can act as anindicatorofprior carnog exposur The presnee ofDNA adducts would, in addition, suggest a mutagenic/car- cinogenic risk to the aquatic orn itself.Wrtebrate fish are chacterized by high levels ofcarcinogen metabolism, low body burdens ofcarcinogen, the formation ofcarcinogen-macromolecule adducs, and theoccurrence ofpollution- related tumor Shellfish, on the other hand, h elowlevesofcarclnogenmetabos, high body burdens ofarcinogen, and have little or no evidence ofcarcinogen-macromolecule adductsor tums Th consumpton ofcarcinogen adducts in aquatic foodt Is unlkely to reprent a human helth hazard.There are no metaboik pathways by which protein- carcinogen or DNA-carcinogen adducts could reform carcnogen Incorporation via salage pathways of prformed mucleoside-carcinogen adducts from fo ts into newly syntbeized human DNA is theo lly ponsihIe However, absolute levelsofnucleoside-carcinogen leves in aquatic foodstuffs from polluted areas arevery low, and the incorpora- tion of peormed adducts into DNA is songly discrminated against by the fidelity of DNA synthesis.
Regulation of hormone-induced Ca2+ mobilization in the human platelets.
Authors: M F Crouch, E G Lapetina
Journal: Environmental Health Perspectives (1990)

alpha-Thrombin, gamma-thrombin, and platelet-activating factor each stimulated the mobilization of intracellular Ca2+ stores in aspirin-treated human platelets. This was followed by desensitization of the receptors, as shown by the return of the Ca2+ level to basal values and by the fact that a subsequent addition of a second different agonist, but not the same agonist, could again elicit a response. Epinephrine, acting on alpha 2-adrenergic receptors, was by itself ineffective at mobilizing Ca2+ stores. However, when added after the thrombin-induced response, epinephrine could evoke a considerable release of Ca2+ from cellular stores. This appeared to be due to epinephrine recoupling thrombin receptors to phospholipase C. In support of this, epinephrine was able to induce the formation of inositol triphosphate when added after the response to thrombin had also become desensitized. Alone, epinephrine was without effect. Pre-activation of protein kinase C with the phorbol ester abolished these effects of epinephrine, suggesting that epinephrine was working by activating a protein which could be inactivated by phosphorylation. Our current work is to characterize this protein that may be a member of the Gi, GTP-binding protein family.
Treatment patterns and clinical outcomes among patients (pts) with HER2+ advanced breast cancer (ABC) and germline <i>BRCA1/2</i> mutation(s) (g<i>BRCA1/2</i>mut): Results from a US real-world study.
Authors: Elias Obeid, Rohan Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens, Lillian Shahied Arruda, Alexander Niyazov
Journal: Journal of Clinical Oncology (2020)

e13076 Background: g BRCA1/2mut ABC represents ~5% of all breast cancer (BC) including pts with HER2+ BC. While HER2-targeted therapy remains an effective tx for those pts, limited information is available on the use and effectiveness of PARP inhibitors (PARPi) for pts with HER2+ g BRCA1/2mut ABC. Recently, NCCN updated its guidelines (v1.2020) to support the use of PARPi in pts with g BRCA1/2mut metastatic BC regardless of subtype. In order to establish a baseline reference point, we assessed real-world tx patterns and clinical outcomes among pts with g BRCA1/2mut HER2+. Methods: Oncologists retrospectively reviewed charts (July-Oct 2019) of randomly selected pts ≥18 y, with g BRCA1/2mut HER2+ABC who received ≥1 cytotoxic chemotherapy (CT) regimen(s) for ABC between Jan 2013-April 2018. Descriptive analysis was performed for 1 st line ABC tx patterns. Clinical outcomes (1 st line ABC PFS rates) were estimated using the Kaplan-Meier method. PARPi clinical outcomes data was immature given its recent launch. Additional analyses evaluating outcomes in pts receiving PARPi are planned. Results: Of the 225 pts with g BRCA1/2mut ABC included in the study, 48 (21%) female pts had HER2+ disease. Of the g BRCA1/2mut HER2+ pts, 77% were white with a median age of 58 y. Clinical characteristics: 42% HR+/HER2+, 56% HR-/HER2+, 2% had unknown HR/HER2+ ABC. Txs in the 1 st line setting for HR+/HER2+ ABC pts (n = 20) included: CT (75%), CT + HER2-targeted therapy (25%) (Table). First-line txs used for HR-/HER2+ ABC pts (n = 27) included: CT + HER2-targeted therapy (78%), CT (15%), other (7%) (Table). 12-month PFS for 1 st line HR+/HER2+ pts was 73% and for HR-/HER2+ pts was 69% (Table). Later line tx patterns will be presented. Conclusions: In this analysis of pts with g BRCA1/2mut HR+/HER2+, unexpectedly low rates of HER2-targeted therapy were observed. As expected, high rates of HER2-targeted therapy with CT were observed among g BRCA1/2mut HR-/HER2+ pts. Clinical outcome findings demonstrate the need for more efficacious tx options. Studies assessing clinical outcomes among g BRCA1/2mut HER2+ ABC pts receiving PARPi +/- HER2-targeted tx are warranted. This is a limited sample size; additional data collection including median PFS is ongoing. [Table: see text]
From the Food and Drug Administration
Authors: Stuart L. Nightingale
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing climb in rates of esophageal adenocarcinoma: an update
Authors: W. J. Blot
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Can Maintenance Therapy for Opportunistic Infections in HIV-Infected People Be Stopped Safely?
Journal: Annals of Internal Medicine (2002)

Summaries for Patients20 August 2002Can Maintenance Therapy for Opportunistic Infections in HIV-Infected People Be Stopped Safely?Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-4-200208200-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?HIV infection damages the body's ability to resist all types of infection, even by organisms that do not usually cause disease in healthy people (opportunistic infections). Because of increased susceptibility to infection, HIV-positive patients are often advised to take preventive antibiotics on a long-term basis to ward off opportunistic infections. Doctors estimate an individual's level of susceptibility to infection by measuring how many of a particular kind of white blood cell (CD4 lymphocytes) are present in the blood. More CD4 lymphocytes in the blood produce a lower susceptibility ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy.” It is in the 20 August 2002 issue of Annals of Internal Medicine (volume 137, pages 239-250). The authors are O Kirk, P Reiss, C Uberti-Foppa, M Bickel, J Gerstoft, C Pradier, FW Wit, B Ledergerber, JD Lundgren, and H Furrer, for Seven European HIV Cohorts.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSafe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy Ole Kirk , Peter Reiss , Caterina Uberti-Foppa , Markus Bickel , Jan Gerstoft , Christian Pradier , Ferdinand W. Wit , Bruno Ledergerber , Jens D. Lundgren , Hansjakob Furrer , and Metrics 20 August 2002Volume 137, Issue 4Page: I-34KeywordsAntibioticsAntiretroviral therapyBloodHIVHIV infectionsLymphocytesOpportunistic infectionsOpportunistic pathogensToxoplasmosisWhite blood cells ePublished: 20 August 2002 Issue Published: 20 August 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
DDRE-12. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
Authors: Sabine Mueller, Mariam Aboian, Kellie Nazemi, Karen Gauvain, Janet Yoon, Jane Minturn, Sarah Leary, Mohamed AbdelBaki, Stewart Goldman, Jennifer Elster, Adam Resnick, Annette Molinaro, Joanna Phillips, Michael Prados, Daphne Haas-Kogan
Journal: Neuro-Oncology (2020)

Abstract OBJECTIVE To estimate the 6-month Progression Free Survival (PFS6) associated with everolimus for progressive/recurrent pLGGs and to determine if activated PI3K/Akt/mTOR pathway as measured by positive phosphorylated-ribosomal protein S6 (p-RPS6) status was associated with response. METHOD Patients 3–21 years of age with recurrent or progressive pLGG were enrolled. Everolimus was administered orally at 5 mg/m2 daily. Tissue availability for molecular analysis was mandatory. Immunohistochemistry (IHC) for p-RPS6 was performed centrally. An adaptive Simon two-stage design was employed based on p-RPS6 status. Based on results of the first stage, enrollment in the second stage was either limited to pathway activated patients or open to all subjects. RESULTS From December 2012 to July 2019 a total of 65 subjects enrolled [median age 9 years (range 3–19); 43% female]. As of December 15, 2019 median number of treatment cycle is 8 (range 1–24); 7 patients remain on treatment. Toxicity profile is similar to published reports with rash and elevated lipid profiles as most common adverse events. PFS6 for the entire cohort is 63%; PFS6 is 64% for the activated and 61% for the non-activated patients. Central imaging review (n=52) revealed 1 partial response, 1 complete response, 33 stable disease, and 17 progressive disease at the end of study treatment. Initial molecular analysis identified BRAF alterations in 35/65 patients. CONCLUSION Everolimus is well tolerated and active in a subset of pLGGs. Ongoing analyses will assess predictive biomarkers of response and will be reported at the meeting.
Commentaries on the end of year editorial on the definition of ischaemia in last December's issue
Authors: R. C Kukreja
Journal: Cardiovascular Research (1995)

Journal Article Commentaries on the end of year editorial on the definition of ischaemia in last December's issue Get access Rakesh C Kukreja, Dr Rakesh C Kukreja, Dr Division of Cardiology, Medical College of Virginia, Richmond, Virginia, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 29, Issue 2, February 1995, Page 291, https://doi.org/10.1016/S0008-6363(95)90014-4 Published: 01 February 1995
Leiomyoma of the Esophagus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal